---
title: "Immvira Bioscience Files Hong Kong Listing Application Under Chapter 18A"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292896415.md"
description: "Immvira Bioscience, a pre-revenue biotechnology company focused on clinical need-driven development, has filed for a Hong Kong listing under Chapter 18A of the Listing Rules, according to Ming Pao reported. Citigroup and CICC (3908) are the joint sponsors."
datetime: "2026-07-16T11:07:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292896415.md)
  - [en](https://longbridge.com/en/news/292896415.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292896415.md)
generator: "portal-rs"
---

# Immvira Bioscience Files Hong Kong Listing Application Under Chapter 18A

Immvira Bioscience, a pre-revenue biotechnology company focused on clinical need-driven development, has filed for a Hong Kong listing under Chapter 18A of the Listing Rules, according to Ming Pao reported. Citigroup and CICC (3908) are the joint sponsors.

### Related Stocks

- [03908.HK](https://longbridge.com/en/quote/03908.HK.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [601995.CN](https://longbridge.com/en/quote/601995.CN.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)

## Related News & Research

- [Alibaba-backed AI Video Platform Shengshu Tech Reportedly Eyes HK Listing Next Yr, Seeking USD500M+](https://longbridge.com/en/news/296285914.md)
- [Lyntris Prices IPO at $17.50, Nets $69.5 Million in Evercore- and Citi-Led Underwriting](https://longbridge.com/en/news/296617491.md)
- [Advisors Preferred LLC Invests $5.42 Million in Neurocrine Biosciences, Inc. $NBIX](https://longbridge.com/en/news/296580338.md)
- [Great Lakes Advisors LLC Acquires Shares of 66,924 Ionis Pharmaceuticals, Inc. $IONS](https://longbridge.com/en/news/296455358.md)
- [XPENG-W  Slumps Nearly 10% at Half-day as Multiple Brokers Say 2Q Losses Beat Expectations; Bullish on Robotics Business](https://longbridge.com/en/news/296860600.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**